DE60132891D1 - Zyklische harnstoffverbindungen und verfahren zu deren herstellung - Google Patents

Zyklische harnstoffverbindungen und verfahren zu deren herstellung

Info

Publication number
DE60132891D1
DE60132891D1 DE60132891T DE60132891T DE60132891D1 DE 60132891 D1 DE60132891 D1 DE 60132891D1 DE 60132891 T DE60132891 T DE 60132891T DE 60132891 T DE60132891 T DE 60132891T DE 60132891 D1 DE60132891 D1 DE 60132891D1
Authority
DE
Germany
Prior art keywords
compounds
carbamic acid
new
function
urea compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60132891T
Other languages
English (en)
Other versions
DE60132891T2 (de
Inventor
Marc Rodriguez
Gilles Guichard
Serge Plaue
Vincent Semetey
Arnaud-Pierre Schaffner
Jean-Paul Briand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
ImmuPharma France SA
Original Assignee
Centre National de la Recherche Scientifique CNRS
ImmuPharma France SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, ImmuPharma France SA filed Critical Centre National de la Recherche Scientifique CNRS
Publication of DE60132891D1 publication Critical patent/DE60132891D1/de
Application granted granted Critical
Publication of DE60132891T2 publication Critical patent/DE60132891T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/04—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/04—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D259/00—Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
DE60132891T 2000-06-13 2001-06-13 Zyklische harnstoffverbindungen und verfahren zu deren herstellung Expired - Lifetime DE60132891T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0007507A FR2810039B1 (fr) 2000-06-13 2000-06-13 Composes urees cycliques et leur procede de preparation
FR0007507 2000-06-13
PCT/FR2001/001837 WO2001096318A1 (fr) 2000-06-13 2001-06-13 Composes urees cycliques et leur procede de preparation

Publications (2)

Publication Number Publication Date
DE60132891D1 true DE60132891D1 (de) 2008-04-03
DE60132891T2 DE60132891T2 (de) 2009-03-19

Family

ID=8851208

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60132891T Expired - Lifetime DE60132891T2 (de) 2000-06-13 2001-06-13 Zyklische harnstoffverbindungen und verfahren zu deren herstellung

Country Status (13)

Country Link
US (1) US7186828B2 (de)
EP (2) EP1640368A3 (de)
JP (1) JP5054877B2 (de)
KR (1) KR20030031001A (de)
AT (1) ATE386728T1 (de)
AU (2) AU2001267645B2 (de)
CA (2) CA2412782C (de)
DE (1) DE60132891T2 (de)
DK (1) DK1289968T3 (de)
ES (1) ES2301554T3 (de)
FR (1) FR2810039B1 (de)
IL (1) IL153408A0 (de)
WO (1) WO2001096318A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006331357B2 (en) * 2005-12-29 2012-05-17 Immupharma France Sa Compositions and methods for synthesizing novel heterocyclic therapeutics
WO2007074170A2 (de) * 2005-12-29 2007-07-05 Immupharma France Sa Compositions and methods for the treatment and prevention of disease
EP1973887B1 (de) * 2005-12-29 2012-09-19 Immupharma France SA Aza-heterocyclen zur behandlung von malaria oder aids
US7777030B2 (en) 2005-12-29 2010-08-17 Centre National de la Recherge Scientifique (CNRS) Compositions and methods for the treatment and prevention of disease
JP2009522234A (ja) * 2005-12-29 2009-06-11 イミュファルマ・フランス・エスアー ホスホリパーゼａ２を阻害する組成物および方法
US8563115B2 (en) 2008-08-12 2013-10-22 Xerox Corporation Protective coatings for solid inkjet applications
US8191992B2 (en) * 2008-12-15 2012-06-05 Xerox Corporation Protective coatings for solid inkjet applications
EP2548869A1 (de) * 2011-07-20 2013-01-23 Cytec Technology Corp. Verfahren zur Herstellung von N-substituierten cyclischen Alkylenharnstoffen
CN102911130B (zh) * 2011-08-03 2015-05-20 北京师范大学 一种一锅法合成脲四元环化合物的方法、合成的脲四元环化合物
EP3466979B1 (de) 2013-08-21 2019-11-06 UREKA Sarl Chimäre peptidoligoharnstoffverbindungen und verfahren zu deren verwendung
US10414722B2 (en) 2015-06-22 2019-09-17 Ureka Sarl Bioinspired catalysis using oligourea helical foldamers
WO2017037142A1 (en) 2015-08-31 2017-03-09 Centre National De La Recherche Scientifique (Cnrs) Foldamer helix bundle-based molecular encapsulation
WO2017182873A2 (en) 2016-04-19 2017-10-26 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
WO2022240894A1 (en) * 2021-05-11 2022-11-17 Celestial Oncology Inc. Coupled robotic radiation therapy system

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2847760A1 (de) * 1978-11-03 1980-05-14 Hoechst Ag Verfahren zur herstellung von 1,3,5-triaza-2,4,6-triketo-cycloheptan- 3,5-di-essigsaeureestern
US4918186A (en) * 1986-05-06 1990-04-17 Mitsui Toatsu Chemicals, Inc. Process for producing cyclic ureas
US5610294A (en) * 1991-10-11 1997-03-11 The Du Pont Merck Pharmaceutical Company Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
BR9206623A (pt) * 1991-10-11 1995-05-02 Du Pont Merck Pharma Uréias cíclicas e análogas úteis como inibidoras da protease retroviral
US5637780A (en) 1993-03-30 1997-06-10 The Dupont Merck Pharmaceutical Company Method for preparing alkylating agents and their use for alkylating cyclic ureas
US5508400A (en) * 1994-04-20 1996-04-16 The Du Pont Merck Pharmaceutical Company Preparation of cyclic urea compounds
AU5310096A (en) * 1995-03-17 1996-10-08 Du Pont Merck Pharmaceutical Company, The Cyclic urea hiv protease inhibitors
US5532356A (en) * 1995-06-06 1996-07-02 The Dupont Merck Pharmaceutical Company Method for preparing N,N'-disubstituted cyclic ureas
US5532357A (en) * 1995-06-07 1996-07-02 The Dupont Merck Pharmaceutical Company Method for preparing N-monosubstituted and N,N'-disubstituted unsymmetrical cyclic ureas
AU1592697A (en) 1995-08-22 1997-03-19 Du Pont Merck Pharmaceutical Company, The Substituted cyclic ureas and derivatives thereof useful as retroviral protease inhibitors
HUP9904143A3 (en) 1996-11-08 2002-11-28 Du Pont Pharm Co (4r,5s,6s,7r)-hexahydro-1- [5-(3-aminoinazole)methyl] -3-butyl-5,6-dihydroxy-4,7-bis [phenylmethyl] -2h-1,3-diazepin-2-one,its preparation and its use as hiv protease inhibitor

Also Published As

Publication number Publication date
JP5054877B2 (ja) 2012-10-24
AU2001267645B2 (en) 2006-07-27
EP1289968B1 (de) 2008-02-20
EP1640368A3 (de) 2007-03-28
CA2412782C (en) 2012-08-07
ES2301554T3 (es) 2008-07-01
IL153408A0 (en) 2003-07-06
EP1289968A1 (de) 2003-03-12
EP1640368A2 (de) 2006-03-29
AU6764501A (en) 2001-12-24
WO2001096318A8 (fr) 2003-05-01
ATE386728T1 (de) 2008-03-15
JP2004503546A (ja) 2004-02-05
WO2001096318A1 (fr) 2001-12-20
DE60132891T2 (de) 2009-03-19
CA2412782A1 (en) 2001-12-20
FR2810039A1 (fr) 2001-12-14
DK1289968T3 (da) 2008-06-23
US20040044199A1 (en) 2004-03-04
CA2778314C (en) 2017-01-03
CA2778314A1 (en) 2001-12-20
FR2810039B1 (fr) 2007-05-25
US7186828B2 (en) 2007-03-06
KR20030031001A (ko) 2003-04-18

Similar Documents

Publication Publication Date Title
DE60132891D1 (de) Zyklische harnstoffverbindungen und verfahren zu deren herstellung
ATE145914T1 (de) Anticonvulsive fructopyranose zyklische sulfate und sulfite
ATE143941T1 (de) Salpetersäureester von 2-(2,6- dihalophenylamino)phenylessigsäurederivaten und verfahren zu ihrer herstellung
IS4734A (is) Merktar frumueiturs-antrasýklín hliðstæður
AU2002310156A1 (en) 1,4-disubstituted benzo-fused cycloalkyl urea compounds
DE122008000006I1 (de) Zyklische Peptide mit antifungischer Wirkung und Verfahren zu ihrer Herstellung
WO2003076458A3 (en) Selective dipeptide inhibitors of kallikrein
HUP9902818A3 (en) Compounds with anti-inflammatory and immunosuppressive activities
DK0726893T3 (da) Hidtil ukendte 4-piperidinyl-substituerede lactamer som neurokinon 2-receptor-antagonister til behandling af astma
ES2127189T3 (es) Peptido nuevo biologicamente activo procedente de una rana (rana-cpn).
AU2003293585A8 (en) Intermediate cefdinir salts
ATE245435T1 (de) Totalsynthese des amino hip analogen von didemnin a
BR0101230A (pt) Processo para a preparação de11-amino-3-cloro-6,11-diidro-5-5-dioxo-6-metil-dibenzo[c,f][1,2]tiazepina e aplicação para a sìntese detianeptina
CO4560412A1 (es) Piperidonas
DK0640081T3 (da) Substituerede phenylcarbarmater og phenylurinstoffer, deres fremstilling og deres anvendelse som 5-HT4-antagonister
CA2093202A1 (en) Sterilant gas mixture
WO2001051479A3 (en) Tricyclic compounds with antiviral activity
SE9800865D0 (sv) New Process
ATE451347T1 (de) N-methyl-homocysteine und ihre verwendung sowie verfahren zu ihrer herstellung
NZ506667A (en) A process for the conversion of echinocandin class of peptides to their c4-homotyrosine monodeoxy analogues
ES2061679T3 (es) Un procedimiento para preparar un peptido.
ATE293638T1 (de) Synthetische antineoplastische wirkstoffe abgeleitet von dolastatin 15 sowie verfahren zu ihrer herstellung
WO2003029284A1 (fr) Agent anti-vih
岩元誠一 On the first subconstituent of a quadratic forms scheme
Li et al. Burgess dehydrating reagent

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: RODRIGUEZ, MARC, F-67000 STRASBOURG, FR

Inventor name: GUICHARD, GILLES, F-67202 WOLFISHEIM, FR

Inventor name: PLAUE, SERGE, F-67500 MARIENTHAL, FR

Inventor name: SEMETEY, VINCENT, F-67000 STRASBOURG, FR

Inventor name: SCHAFFNER, ARNAUD-PIERRE, F-67115 PLOBSHEIM, FR

Inventor name: BRIAND, JEAN-PAUL, F-67000 STRASBOURG, FR

8364 No opposition during term of opposition